We offer a wide range of support and services to market access and HEOR teams from global to local level, including: evidence and market access strategy development; the generation and assimilation of evidence; and implementation and communication to payers and other stakeholders.  Our team of in-house market access consultants, health economists, writers, analysts and developers are experienced and skilled, and ready to help you with your latest market access challenge. We have access to a broad network of payers, clinicians and other stakeholders across global markets, who we regularly engage to inform our insights and recommendations.

Evidence

Strategy, generation and planning

  • Evidence generation strategy
  • Systematic literature review
  • Meta-analysis
  • Health economic evaluation
  • Data analytics
  • Early scientific advice strategy and support
Read more

Value and access

Strategy and insight

  • Value demonstration strategy
  • Market access and pricing strategy
  • Value proposition development and testing
  • Landscape and situation analysis
  • Primary research and advisory boards
Read more

Communication

Implementation and support

  • Cross-market HTA/reimbursement submissions
  • Value dossiers
  • Budget impact models
  • Market-leading digital communication solutions
  • Publications
  • Payer engagement strategy
Read more

NHS Insights & Interaction

UK market access strategy illuminated by authentic NHS insights

Evidence

Strategy, generation and planning

A robust, comprehensive evidence base is crucial in demonstrating the effectiveness and, ultimately, the value of your product to payers and other key stakeholders. Our team of market access experts and evidence-based scientists will support you in understanding the evidence needed to achieve success, and in the planning, execution and implementation of evidence generation activities to support your access strategy.

Read more

Value and access

Strategy and insight

In a highly dynamic and evolving global healthcare environment, demonstrating the value of your product is key to ensuring patient access and achieving commercial success. Our experts will support you in understanding the market landscape and value of your product, and in developing robust value, market access and pricing strategies, as well as developing and validating value propositions.

Read more

Communication

Implementation and support

It is essential to communicate the clinical and economic value of your product in a way that resonates with the many stakeholders in access and reimbursement decision-making. Our consultants and communication experts will guide you through reimbursement and health technology assessment (HTA) submissions process, where evidence and value determine access decisions. Our health economic modellers will quantify the financial benefits of product adoption, and our experienced digital team are world-leaders in developing engaging, interactive value communication tools for use with payers and clinicians.

Read more

Latest news

At Mtech Access we are always striving to engage with the wider market access community and share our thoughts on the latest industry issues or methods development.

NHS Insights
21/11/2019

How will you stay on top of changes in the NHS in 2020?

A new government will mean new Health & Social care policy; reorganisations may follow and funding will most definitely be impacted. We are in a time of great change in...
Meta-analysisSystematic ReviewISPOR
20/11/2019

ISPOR Europe 2019 – The inspiration behind our poster presentations

Nine of our senior team made the trip to Copenhagen to represent Mtech Access at ISPOR Europe this November. The conference brought together leading experts from across Health Economics and Outcomes...
Health Economics
18/09/2019

Should NICE consider a broader societal perspective when assessing new gene therapies?

Dan Howard and Hannah Gillies from our Health Economics team explore some of the themes from a recent Health Affairs Blog article on the implications of new cell and gene therapies on HTA:   ‘Putting The Costs And...
View all news